Physician profile
Michael D Banas
NPI 1447283288
$8,450.94
in general payments reported to CMS, 2019-2025
45 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $707 · 2021: $868 · 2022: $1,338 · 2023: $1,557 · 2024: $1,802 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,458.29 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,009.04 | 2019-2025 | |
| Pfizer INC. | $659.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $526.12 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $515.78 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $326.66 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $323.63 | 2020-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $274.70 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.32 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $223.02 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $204.57 | 2021-2025 | Onpattro |
| Edwards Lifesciences Corporation | $198.84 | 2020-2025 | Sapien 3 Ultra Resilia |
| Itamar Medical INC | $149.09 | 2023-2024 | Watchpatone |
| Boston Scientific Corporation | $144.85 | 2019-2024 | Watchman Flx |
| Kiniksa Pharmaceuticals, LTD. | $144.82 | 2022-2023 | Arcalyst |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $141.25 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $135.47 | 2023-2025 | Optimizer, Optimizer |
| Scpharmaceuticals INC. | $135.00 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $123.91 | 2020-2022 | |
| Abbott Laboratories | $118.09 | 2019-2025 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $114.39 | 2020-2023 | |
| Ge Healthcare | $113.21 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $103.98 | 2023-2024 | Inpefa |
| Irhythm Technologies, INC. | $97.34 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Novo Nordisk INC | $96.61 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abiomed | $91.19 | 2023-2025 | Impella |
| Bridgebio Pharma, INC. | $89.10 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $86.34 | 2021-2022 | |
| Heartflow, INC. | $67.28 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $65.69 | 2024-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $57.18 | 2021-2024 | Nexletol |
| Medtronic Vascular, INC. | $52.92 | 2019 | |
| Kestra Medical Technology Services, INC. | $50.95 | 2023 | Assure Wcd |
| Medline Industries LP | $47.02 | 2025 | |
| Recor Medical INC | $45.99 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Lilly USA, LLC | $40.82 | 2025 | Mounjaro, Zepbound |
| Cvrx, INC. | $31.96 | 2024 | Barostim Neo System |
| Preventice Services, LLC | $28.93 | 2021 | |
| Gilead Sciences, INC. | $26.99 | 2019 | |
| Lundbeck LLC | $21.57 | 2020 | |
| Inspire Medical Systems, INC. | $19.36 | 2025 | Inspire |
| Daiichi Sankyo INC. | $18.59 | 2022 | |
| Corcept Therapeutics | $16.36 | 2025 | Korlym |
| Amarin Pharma, INC. | $14.85 | 2019 | |
| Medtronic, INC. | $14.18 | 2023 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Banas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.